CR20210024A - Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 - Google Patents
Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1Info
- Publication number
- CR20210024A CR20210024A CR20210024A CR20210024A CR20210024A CR 20210024 A CR20210024 A CR 20210024A CR 20210024 A CR20210024 A CR 20210024A CR 20210024 A CR20210024 A CR 20210024A CR 20210024 A CR20210024 A CR 20210024A
- Authority
- CR
- Costa Rica
- Prior art keywords
- interleukin
- inhibitors
- activity
- sulfonylurea compounds
- nlrp3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>La presente divulgación se refiere a compuestos de sulfonilurea y compuestos relacionados útiles en el tratamiento de un trastorno sensible a la modulación de citocinas tales como IL-1β e IL-18, modulación de NLRP3 o inhibición de la activación de NLRP3 o componentes relacionados del proceso inflamatorio</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701358P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042703 WO2020018970A1 (en) | 2018-07-20 | 2019-07-19 | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210024A true CR20210024A (es) | 2021-02-22 |
Family
ID=67515207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210024A CR20210024A (es) | 2018-07-20 | 2019-07-19 | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11560391B2 (es) |
| EP (1) | EP3823726A1 (es) |
| JP (1) | JP7411631B2 (es) |
| KR (1) | KR20210034588A (es) |
| CN (1) | CN112437683A (es) |
| AR (1) | AR117617A1 (es) |
| AU (1) | AU2019305095A1 (es) |
| BR (1) | BR112021001012A2 (es) |
| CA (1) | CA3104199A1 (es) |
| CL (1) | CL2021000152A1 (es) |
| CO (1) | CO2021000817A2 (es) |
| CR (1) | CR20210024A (es) |
| IL (1) | IL280139A (es) |
| MA (1) | MA53170A (es) |
| MX (1) | MX2021000660A (es) |
| PE (1) | PE20211049A1 (es) |
| PH (1) | PH12020552155A1 (es) |
| SG (1) | SG11202012159TA (es) |
| TW (1) | TW202019937A (es) |
| WO (1) | WO2020018970A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA47308A (fr) | 2017-01-23 | 2019-11-27 | Genentech Inc | Composés chimiques comme inhibiteurs de l'activité interleukine-1 |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| PE20200758A1 (es) | 2017-08-15 | 2020-07-27 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| MA50567A (fr) | 2017-11-09 | 2020-09-16 | Inflazome Ltd | Nouveaux composés de sulfonamide carboxamide |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| US20220378801A1 (en) | 2019-06-21 | 2022-12-01 | Ac Immune Sa | Novel compounds |
| MX2022005732A (es) * | 2019-11-12 | 2022-06-09 | Chengdu Baiyu Pharmaceutical Co Ltd | Derivado de amida y metodo de preparacion para el mismo y uso del mismo en medicina. |
| BR112022025612A2 (pt) | 2020-06-19 | 2023-01-17 | Ac Immune Sa | Derivados de di-hidro-oxazol e tioureia modulando a via do inflamassoma nlrp3 |
| WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| US20230279026A1 (en) * | 2022-02-21 | 2023-09-07 | Viva Star Biosciences (Suzhou) Co., Ltd. | Novel bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity |
| US20240034735A1 (en) | 2022-07-14 | 2024-02-01 | Ac Immune Sa | Novel compounds |
| US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| PL335052A1 (en) | 1997-01-29 | 2000-03-27 | Pfizer | Derivatives of sulphonylurea and their application in regulating activity of interleukin-1 |
| AU6464400A (en) | 1999-09-14 | 2001-04-17 | Pfizer Products Inc. | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
| WO2003045400A1 (en) | 2001-11-30 | 2003-06-05 | Pfizer Products Inc. | Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation |
| JP6152643B2 (ja) * | 2010-02-22 | 2017-06-28 | 株式会社ＡｓｋＡｔ | Ｉｌ−２３媒介疾患を治療するためのｅｐ４受容体拮抗薬の使用 |
| KR20140075698A (ko) | 2011-09-02 | 2014-06-19 | 교와 핫꼬 기린 가부시키가이샤 | 케모카인 수용체 활성 조절제 |
| CN113582889A (zh) | 2015-02-16 | 2021-11-02 | 昆士兰大学 | 磺酰脲和相关化合物及其用途 |
| CA3014487A1 (en) | 2016-02-16 | 2017-08-24 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Sulfonylureas and related compounds and use of same |
| ES2940611T3 (es) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| ES2927777T3 (es) | 2016-04-18 | 2022-11-10 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| MA47308A (fr) * | 2017-01-23 | 2019-11-27 | Genentech Inc | Composés chimiques comme inhibiteurs de l'activité interleukine-1 |
| CA3059458A1 (en) | 2017-05-24 | 2018-11-29 | The University Of Queensland | Novel compounds and uses |
| US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| PE20212077A1 (es) | 2017-07-07 | 2021-10-28 | Inflazome Ltd | Nuevos compuestos sulfonamida de carboxamida |
| US11542255B2 (en) | 2017-08-15 | 2023-01-03 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| PE20200758A1 (es) | 2017-08-15 | 2020-07-27 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| MX2020001777A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Compuestos novedosos. |
| US11773058B2 (en) | 2017-08-15 | 2023-10-03 | Inflazome Limited | Sulfonamide carboxamide compounds |
| WO2019034688A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| MA50567A (fr) | 2017-11-09 | 2020-09-16 | Inflazome Ltd | Nouveaux composés de sulfonamide carboxamide |
| EP3707137A1 (en) | 2017-11-09 | 2020-09-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| CN112584899A (zh) | 2018-07-03 | 2021-03-30 | 诺华股份有限公司 | Nlrp调节剂 |
| JP2021529780A (ja) | 2018-07-03 | 2021-11-04 | ノバルティス アーゲー | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 |
| US10981918B2 (en) | 2018-07-20 | 2021-04-20 | Grünenthal GmbH | Further substituted triazolo quinoxaline derivatives |
| BR112021001044A2 (pt) | 2018-07-20 | 2021-04-13 | F. Hoffmann-La Roche Ag | Compostos de sulfonimidamida como inibidores da atividade de interleucina-1 |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| US20220194923A1 (en) | 2018-08-15 | 2022-06-23 | Inflazome Limited | Novel sulfonamideurea compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| US20230011652A1 (en) | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| CN113316566A (zh) | 2019-01-22 | 2021-08-27 | 诺华股份有限公司 | 用于治疗与nlrp活性相关的病症的化合物和组合物 |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
-
2019
- 2019-07-19 MA MA053170A patent/MA53170A/fr unknown
- 2019-07-19 BR BR112021001012-2A patent/BR112021001012A2/pt not_active Application Discontinuation
- 2019-07-19 JP JP2021502998A patent/JP7411631B2/ja active Active
- 2019-07-19 CN CN201980048411.9A patent/CN112437683A/zh active Pending
- 2019-07-19 CR CR20210024A patent/CR20210024A/es unknown
- 2019-07-19 KR KR1020217001676A patent/KR20210034588A/ko unknown
- 2019-07-19 WO PCT/US2019/042703 patent/WO2020018970A1/en unknown
- 2019-07-19 AU AU2019305095A patent/AU2019305095A1/en not_active Abandoned
- 2019-07-19 SG SG11202012159TA patent/SG11202012159TA/en unknown
- 2019-07-19 CA CA3104199A patent/CA3104199A1/en active Pending
- 2019-07-19 EP EP19749134.3A patent/EP3823726A1/en active Pending
- 2019-07-19 MX MX2021000660A patent/MX2021000660A/es unknown
- 2019-07-19 PE PE2021000074A patent/PE20211049A1/es unknown
- 2019-07-22 TW TW108125890A patent/TW202019937A/zh unknown
- 2019-07-22 AR ARP190102054A patent/AR117617A1/es unknown
-
2020
- 2020-12-14 PH PH12020552155A patent/PH12020552155A1/en unknown
-
2021
- 2021-01-12 IL IL280139A patent/IL280139A/en unknown
- 2021-01-15 US US17/150,380 patent/US11560391B2/en active Active
- 2021-01-19 CL CL2021000152A patent/CL2021000152A1/es unknown
- 2021-01-26 CO CONC2021/0000817A patent/CO2021000817A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019305095A1 (en) | 2020-12-17 |
| PE20211049A1 (es) | 2021-06-04 |
| MA53170A (fr) | 2021-05-26 |
| JP2021530536A (ja) | 2021-11-11 |
| EP3823726A1 (en) | 2021-05-26 |
| IL280139A (en) | 2021-03-01 |
| CA3104199A1 (en) | 2020-01-23 |
| WO2020018970A1 (en) | 2020-01-23 |
| TW202019937A (zh) | 2020-06-01 |
| CN112437683A (zh) | 2021-03-02 |
| BR112021001012A2 (pt) | 2021-04-20 |
| SG11202012159TA (en) | 2021-01-28 |
| AR117617A1 (es) | 2021-08-18 |
| MX2021000660A (es) | 2021-03-25 |
| JP7411631B2 (ja) | 2024-01-11 |
| US11560391B2 (en) | 2023-01-24 |
| US20210261568A1 (en) | 2021-08-26 |
| CO2021000817A2 (es) | 2021-02-17 |
| PH12020552155A1 (en) | 2021-07-05 |
| CL2021000152A1 (es) | 2021-07-09 |
| KR20210034588A (ko) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210022A (es) | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 | |
| CR20210024A (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 | |
| PH12019501611A1 (en) | Chemical compounds as inhibitors of interleukin-1 activity | |
| JOP20220008A1 (ar) | مثبطات parp1 | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| NZ772349A (en) | Sulfonylureas and related compounds and use of same | |
| MX2018009773A (es) | Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4). | |
| MX2022001061A (es) | Agentes de interleuquina-2 y usos de los mismos. | |
| WO2015031679A3 (en) | Modulation of prekallikrein (pkk) expression | |
| CL2020003083A1 (es) | Inhibidores de masp-2 y métodos de uso | |
| MX2021010545A (es) | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar. | |
| MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
| MX2022009309A (es) | Compuestos y usos de los mismos. | |
| PH12017501980A1 (en) | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) | |
| MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
| CA3082254A1 (en) | Heterocyclic compounds as kinase inhibitors | |
| MX2022006750A (es) | Inhibidores de masp-2 y metodos de uso. | |
| MX2022009366A (es) | Compuestos y usos de estos. | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
| WO2021113690A9 (en) | Masp-2 inhibitors and methods of use | |
| MX2020007342A (es) | Compuestos de sililetinilo hetarilo como inhibidores de la nitrificacion. | |
| MX2022007874A (es) | Compuestos y derivados de hidroxiestilbeno sustituido, síntesis y usos de los mismos. | |
| MX2021005171A (es) | Inhibidores de cinasas reguladas por señal extracelular (erk) y usos de los mismos. | |
| CR20230518A (es) | Compuestos y usos de estos |